Axovant Sciences Ltd (NASDAQ:AXON) traded down 0% during mid-day trading on Monday . The stock traded as low as $1.43 and last traded at $1.45. 2,780,900 shares traded hands during trading, an increase of 40% from the average session volume of 1,988,178 shares. The stock had previously closed at $1.45.
Several equities research analysts have issued reports on the stock. ValuEngine raised shares of Axovant Sciences from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Zacks Investment Research raised shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a research note on Wednesday, January 31st. Piper Jaffray Companies reissued a “hold” rating on shares of Axovant Sciences in a research report on Friday, November 10th. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Axovant Sciences in a research report on Friday, December 1st. Finally, Cowen reissued a “hold” rating on shares of Axovant Sciences in a research report on Tuesday, February 13th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the stock. Axovant Sciences has a consensus rating of “Hold” and an average price target of $13.61.
The company has a debt-to-equity ratio of 0.45, a quick ratio of 4.58 and a current ratio of 4.58. The stock has a market cap of $155.10 and a PE ratio of -0.61.
ILLEGAL ACTIVITY NOTICE: This report was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3224070/axovant-sciences-axon-stock-price-down-0.html.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.